DCN-type NEDD8 E3 ligases: Structure, biological function and small-molecule inhibitor

Defective in cullin neddylation 1-5 (DCN1-5) are critical E3 ligases of the neddylation pathway that participate in post-translational modification by selectively catalyzing cullin neddylation, thus mediating the activation of Cullin-RING Ligases (CRLs), and further modulating the activity of target proteins. Currently, DCN1-5 have been identified to play vital roles in cancer, fibrotic diseases, and several other human diseases. Inhibitors targeting DCN1 with various chemotypes had been developed and evaluted in cancer and many NRF2-related diseases. As described above, this review provides insights into the structure and biological functions of DCN1-5, emphasizes the medicinal chemistry advances in the development of DCN1-5 inhibitors, and discusses these five E3 enzymes as appealing therapeutic targets for the treatment of human diseases.

Authors

Institutions

Publication Details

Journal
Pharmacological Research
Published
2026-02-21
DOI
https://doi.org/10.1016/j.phrs.2026.108151
Primary Topic
Ubiquitin and proteasome pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DCN-type NEDD8 E3 ligases: Structure, biological function and small-molecule inhibitor

Chenhao Xu, Wenjuan Zhou, Tingting Liu, Ole Andreas Andreassen et al.
Pharmacological Research
Ubiquitin and proteasome pathways
article

DCN-type NEDD8 E3 ligases: Structure, biological function and small-molecule inhibitor

Chenhao Xu, Wenjuan Zhou, Tingting Liu, Ole Andreas Andreassen, Shengnan Zhang, Tian Zhou, Liying Ma, Xiaohang Song
article en

Abstract

Defective in cullin neddylation 1-5 (DCN1-5) are critical E3 ligases of the neddylation pathway that participate in post-translational modification by selectively catalyzing cullin neddylation, thus mediating the activation of Cullin-RING Ligases (CRLs), and further modulating the activity of target proteins. Currently, DCN1-5 have been identified to play vital roles in cancer, fibrotic diseases, and several other human diseases. Inhibitors targeting DCN1 with various chemotypes had been developed and evaluted in cancer and many NRF2-related diseases. As described above, this review provides insights into the structure and biological functions of DCN1-5, emphasizes the medicinal chemistry advances in the development of DCN1-5 inhibitors, and discusses these five E3 enzymes as appealing therapeutic targets for the treatment of human diseases.

Pharmacological ResearchVol. 225
Oslo University Hospital (NO), Liaoning Normal University (CN), Zhengzhou University (CN), Zhengzhou Children's Hospital (CN)
Openalex Percentile: Top 46%
Ubiquitin and proteasome pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.